Did you get your blubber?

Your blood resin test is a routine check-up in the medical examination. The main components of blood resin are cholesterol, triester glycerine, phosphorus and free fat, 70 per cent of which are synthesized in the body, 30 per cent are absorbed in food digestion, the main part of the body is in tissue cell oxidation, form biofilm and enter the lipid bank. Anomalous is the most important risk factor leading to the hardening of the aneurysm. The sclerosis of the artery is an independent risk factor leading to cardiovascular disease and the surrounding vascular disease, and the sclerosis of the artery (ASCVD) is the first cause of death in the country ‘ s urban and rural inhabitants, accounting for over 40 per cent of deaths. In the face of the increasing burden of cardiac disease in our artery porridge samples, the management of blood resin is of the utmost urgency.Because of the fact that the increase in blubber itself has no symptoms, our population has a low rate of haemorrhagic knowledge, treatment and control of 16.1 per cent, 7.8 per cent and 4.0 per cent, respectively. Therefore, hematoma cannot be detected by clinical performance alone, and hematological examinations are necessary to detect and detect haemorrhagic abnormalities in a timely manner.1. Pre-inspection main issuesBlood is collected in the early morning for more than 12 hours, high-fat diets and non-drinking the day before the blood is taken, and medications that can affect the lipid level, such as contraceptives, some depressants, etc., are not used before the examination.2. How to look at blood resin testsThe regular programmes for blood resin testing include total cholesterol (TC), triester glycerine (TG), low-density protein cholesterol (LDL-C), high-density protein cholesterol (HDL-C), lipid protein A (ApoA), lipid protein B (ApoB), Lp(a), etc. LDL-C is the pathological risk factor for ASCVD, and the most critical for people with cardiovascular diseases and surrounding vascular diseases is to reduce LDL-C. The normal extent of haemoglobin control varies according to specific indicators and individual circumstances, and it is not possible to simply see whether the arrows in the test list are gills or gills, and different blood resin targets are required depending on the risk of cardiovascular disease in the future of the population.3. The reduction target values of LDL-C in accordance with China ‘ s blood resin management guidelines 2023[1] are:(1) The diagnosis of coronary heart disease, ischaemic cerebral organs, perivascular diseases, diabetes combined protein urine, diabetes associated with high-risk factors, severe chronic kidney diseases, LDL-C<1.4mmol/L;(2) Diabetes diabetics older than 40 years of age and 1.8 mmol/L≤LDL-C<4.9 or 3.1 mmol/L≤TC<7.2 mmol/L, hypertensive pressure combines three other cardiovascular risk factors, hypertensive pressure combines two other cardiovascular risk factors and 2.6 mmol/L≤LDL-C<4.9 mmol/L, LDL-C ≥4.9 mmol/L or TC 7.2 mmol/L, other cardiovascular risk factors ≥2, which are at high risk, LDL-C<1.8 mmol/L;(3) High blood pressure combines two other cardiovascular risk factors and LDL-C<2.6mmol/L, hypertension combines one other risk factor and 2.6 mmol/L≤LDL-C<4.9 mmol/L is a medium-risk patient, LDL-C<2.6mmol/L;(4) High blood pressure combines one other cardiovascular risk factor and LDL-C<2.6 mmol/L, free of hypertension but LDL-C≥1.8 mmol/L is a low-risk patient, LDL-C<3.4mmol/L.Other cardiovascular risk factors include age 45-55 (male/female), smoking, HDL-C<1.0 mmol/L, body mass index 28 kg/m2, and the family history of premature ischaemic cardiovascular disease.4. How to reduce lipid treatment(a) A reasonable diet that limits the intake of high cholesterol and high fat foods and the consumption of more cellulose-rich foods, such as vegetables and fruits, and maintains a clean diet;Good blood resin management can significantly reduce the incidence of major cardiovascular events and increase the benefits for patients. Patients with haemoglobin abnormalities should be treated at an early stage of detection, and in accordance with the guidelines, they are recommended for the ASCVD hazard stratification, which is sustained by appropriate deflation drugs based on lifestyle improvement and control of risk factors.Reference [1] Guidelines for management of blood resin in China to revise Joint Expert Committee. Guidelines for management of blood resin in China (2023) [J]. China Cycle Journal, 2023,38(3):237-271 Hematoma.